Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2013 3
2014 1
2015 3
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary arterial hypertension.
Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, Artaud-Macari E, Price LC, Humbert M, Simonneau G, Sitbon O. Montani D, et al. Orphanet J Rare Dis. 2013 Jul 6;8:97. doi: 10.1186/1750-1172-8-97. Orphanet J Rare Dis. 2013. PMID: 23829793 Free PMC article. Review.
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease leading to right heart failure and ultimately death if untreated. ...Group 4 includes chronic thromboembolic pulmonary hypertension without any distinction of proximal or …
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease leading to right heart failure and ultimatel …
Ambrisentan for the management of pulmonary arterial hypertension.
Cheng JW. Cheng JW. Clin Ther. 2008 May;30(5):825-33. doi: 10.1016/j.clinthera.2008.05.005. Clin Ther. 2008. PMID: 18555930 Review.
BACKGROUND: Approved by the US Food and Drug Administration in 2007, ambrisentan is the second oral endothelin A-receptor antagonist available for the management of pulmonary arterial hypertension (PAH) in patients with World Health Organization class …
BACKGROUND: Approved by the US Food and Drug Administration in 2007, ambrisentan is the second oral endothelin A-receptor antagonist …
Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
Aversa M, Porter S, Granton J. Aversa M, et al. Drug Saf. 2015 May;38(5):419-35. doi: 10.1007/s40264-015-0275-y. Drug Saf. 2015. PMID: 25792028 Review.
Pulmonary arterial hypertension (PAH) is a condition that leads to progressive right heart failure and death unless recognized and treated early. ...Although bosentan increases a patient's risk of developing liver transaminitis, ambrisentan and …
Pulmonary arterial hypertension (PAH) is a condition that leads to progressive right heart failure and death unless rec …
A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M, Grimm D, Wehland M, Simonsen U, Infanger M, Krüger M. Bedan M, et al. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):103-113. doi: 10.1111/bcpt.13033. Epub 2018 Jun 5. Basic Clin Pharmacol Toxicol. 2018. PMID: 29719121 Free article. Review.
The approval of macitentan has increased the number of pharmacological treatments of pulmonary arterial hypertension (PAH). Here, we review the effect on PAH of macitentan compared to other endothelin receptor antagonists. ...Macitentan exhibits higher antago …
The approval of macitentan has increased the number of pharmacological treatments of pulmonary arterial hypertension (P …
Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Vizza CD, Fedele F, Pezzuto B, Rubin LJ. Vizza CD, et al. Expert Opin Drug Saf. 2012 Nov;11(6):1003-11. doi: 10.1517/14740338.2012.714770. Epub 2012 Aug 4. Expert Opin Drug Saf. 2012. PMID: 22861496
INTRODUCTION: Pulmonary arterial hypertension (PAH) is characterized by an increase in pulmonary vascular resistance, which can lead to right heart failure and death. ...On the other hand, ambrisentan shows a higher rate of other adverse events, …
INTRODUCTION: Pulmonary arterial hypertension (PAH) is characterized by an increase in pulmonary vascular resist …
Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN, Krähenbühl S, Dingemanse J. Sidharta PN, et al. Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):437-49. doi: 10.1517/17425255.2015.1000859. Epub 2015 Jan 21. Expert Opin Drug Metab Toxicol. 2015. PMID: 25604973 Review.
INTRODUCTION: Pulmonary arterial hypertension (PAH) is a chronic disorder of the pulmonary vasculature characterized by elevated mean pulmonary arterial pressure eventually leading to right-sided heart failure and premature death. ...The …
INTRODUCTION: Pulmonary arterial hypertension (PAH) is a chronic disorder of the pulmonary vasculature character …
Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Dingemanse J, et al. Expert Opin Drug Saf. 2014 Mar;13(3):391-405. doi: 10.1517/14740338.2014.859674. Epub 2013 Nov 22. Expert Opin Drug Saf. 2014. PMID: 24261583 Review.
In vitro and in vivo animal studies have demonstrated its potency in antagonizing endothelin-induced disorders. A large morbidity/mortality study in patients with pulmonary arterial hypertension (PAH) taking macitentan has been completed recently. ...The safe …
In vitro and in vivo animal studies have demonstrated its potency in antagonizing endothelin-induced disorders. A large morbidity/mortality …
A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.
Zhang YJ, Wang N, Gu ZC, Wei AH, Cheng AN, Fang SS, Du HL, Wang LZ, Zhang GQ. Zhang YJ, et al. Cardiovasc Diagn Ther. 2019 Jun;9(3):239-249. doi: 10.21037/cdt.2019.03.02. Cardiovasc Diagn Ther. 2019. PMID: 31275814 Free PMC article.
BACKGROUND: Currently, direct comparative safety between endothelin receptor antagonists (ERAs) in pulmonary arterial hypertension (PAH) is limited. Thus, a systematic review with network analysis was conducted. ...CONCLUSIONS: Abnormal liver function (bos …
BACKGROUND: Currently, direct comparative safety between endothelin receptor antagonists (ERAs) in pulmonary arterial hyper …
Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
Muraoka H, Imamura T, Hatano M, Maki H, Yao A, Kinugawa K, Komuro I. Muraoka H, et al. Int Heart J. 2015;56(4):471-3. doi: 10.1536/ihj.15-007. Epub 2015 Jun 18. Int Heart J. 2015. PMID: 26084462 Free article.
Although endothelin receptor antagonists (ERAs) including bosentan and ambrisentan are essential tools for the treatment of pulmonary arterial hypertension (PAH), each agent has a specific adverse effect with non-negligible frequency, ie, liver …
Although endothelin receptor antagonists (ERAs) including bosentan and ambrisentan are essential tools for the treatment of …
[Efficiency of initiation with ambrisentan versus bosentan in the treatment of pulmonary arterial hypertension].
Villa G, Morano R, Román A, Gil J. Villa G, et al. Farm Hosp. 2013 Sep-Oct;37(5):358-65. doi: 10.7399/FH.2013.37.5.736. Farm Hosp. 2013. PMID: 24128097 Free article. Spanish.
OBJECTIVE: To evaluate the efficiency of initiation with endothelin receptor antagonists, ambrisentan or bosentan, followed by sequential combination with phosphodiesterase-5 inhibitors and prostanoids in the treatment of pulmonary arterial hyperten …
OBJECTIVE: To evaluate the efficiency of initiation with endothelin receptor antagonists, ambrisentan or bosentan, followed by …